Safety Report of TAS-102 in a Patient With Reduced DPD Activity
Abstract
Fluoropyrimidines (5-fluorouracil [5-FU] and its prodrug capecitabine) are widely used alone or in combination with other chemotherapy, and they are the backbone treatment for many solid tumors. The use of these drugs might be associated with severe gastrointestinal and hematologic grade 3 to 4...
Paper Details
Title
Safety Report of TAS-102 in a Patient With Reduced DPD Activity
Published Date
Dec 1, 2019
Journal
Volume
18
Issue
4
Pages
310 - 312
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History